Lupus anticoagulant and anticardiolipin antibodies are high risk factors for repeated abortion and intrauterine death.'13 These factors have been associated with arterial or venous thrombosis, or both. Lupus anticoagulant interferes at the level of the prothrombin activation complex of the clotting cascade4 and may interfere with the production ofprostacyclin by the vessel wall and other tissues, including the myometrium, during pregnancy. 5 It was noted that treatment with high dose prednisolone (40-60 mg/day) in combination with aspirin (75 mg/day) improved fetal survival in pregnant women with lupus anticoagulant and poor obstetric history.' 6 Such treatment for several months sometimes causes serious maternal adverse reactions, however, and the effect of high dose prednisolone on the fetus is unknown. In addition, therapeutic benefits are not always obtained and, therefore, alternative treatments should be evaluated.
Recently, treatment immunoassay. The normal value was less than 10 U/ml.
Case report A 34 year old woman was referred to our hospital during the 18th week of her fourth pregnancy. She had systemic lupus erythematosus, which had been diagnosed in 1976. Since 1978 she had been taking 5-10 mg prednisolone daily and had not had any serious illness or disorders except for three previous spontaneous abortions, which all occurred between the 16th and 24th week of gestation and had been treated with prednisolone at a maximum dose of 40 mg/ day during pregnancy. Results of physical examination, routine biochemistry, and urine analysis were normal. Her erythrocyte sedimentation rate was 72 mm/h, antinuclear factor was positive (1/1280), and antibodies to DNA were 18-5 U/ml (normal <10-0 U/ml). Antibodies to SSA and SSB were negative. Serum immunoglobulin and complement concentrations were normal. Coagulation studies showed a normal prothrombin time with a prolonged APTT of 43 (fig 2) . Although the levels of antibodies to DNA and anticardiolipin antibodies while the prednisolone dose was 5 mg/ day were significantly decreased by plasmapheresis (p<0c01, p<0 05 respectively) the APTT did not show significant change by Mann-Whitney analysis (p>008). As the prednisolone dose was increased during the 24th week of gestation and the fetal growth retardation and oligohydramnios occurred at the 34th week, however, adsorbent plasmapheresis may not be a potent treatment for patients with the lupus anticoagulant syndrome. The possibility must be considered that not only is the removal of lupus anticoagulant and anticardiolipin antibodies required but also production of these antibodies must be suppressed by treatment with medium or high doses of prednisolone.
There are two reasons why we consider that the immunoadsorbent plasmapheresis had a favourable effect in preventing abortion. Firstly, the patient was able to maintain her pregnancy until the end of the 23rd week of gestation with prednisolone as low as S mg/day, though she had had three previous abortions between 16 and 24 weeks gestation while receiving 20-40 mg/day prednisolone. It has been reported that up to 68% of fetal deaths occur during 0-20 weeks of gestation in patients with systemic lupus erythematosus who have lupus anticoagulant and anticardiolipin antibodies. 7 Secondly, despite the focal and decidual infarctions of the placenta she was able to continue her pregnancy with relatively low doses of prednisolone (average 13-95 mg/day).
In conclusion, immunoadsorbent plasmapheresis using dextran sulphate was considered to be a useful prophylactic treatment for reducing the risk of recurrent spontaneous abortion in patients with the antiphospholipid syndrome. It is a possible alternative treatment, especially for patients whose condition cannot be controlled with high dose prednisolone or immunosuppressant drugs, or both, or for those who have adverse reactions to steroid treatment.
